MGN
MCID: MMB011
MIFTS: 54

Membranous Nephropathy (MGN) malady

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Membranous Nephropathy

Aliases & Descriptions for Membranous Nephropathy:

Name: Membranous Nephropathy 54 12 50 14
Membranous Glomerulonephritis 12 50 14 69
Membranous Nephropathy, Susceptibility to 54 29 13
Idiopathic Membranous Glomerulonephritis 56 69
Idiopathic Membranous Nephropathy 50 52
Glomerulonephritis, Membranous 50 42
Membranous Glomerulonephritis, Antenatal 54
Extramembranous Glomerulonephritis 50
Nephropathy Membranous 52
Membranous Gn 50
Mgn 50

Classifications:

Orphanet: 56  
Rare renal diseases


External Ids:

OMIM 54 614692
Disease Ontology 12 DOID:10976
ICD10 33 N03.2
MeSH 42 D015433
NCIt 47 C34645
SNOMED-CT 64 197710000 77182004
Orphanet 56 ORPHA97560
ICD10 via Orphanet 34 N04.2
UMLS 69 C0017665

Summaries for Membranous Nephropathy

OMIM : 54 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of... (614692) more...

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to focal segmental glomerulosclerosis and alport syndrome and thin basement membrane nephropathy. An important gene associated with Membranous Nephropathy is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are NF-kappaB Signaling and Phagosome. The drugs Candesartan and Cilnidipine have been mentioned in the context of this disorder. Affiliated tissues include kidney, neutrophil and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

NIH Rare Diseases : 50 membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. when the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. in many cases, the underlying cause of membranous nephropathy is not known. some cases are associated with other conditions (lupus), infections (hepatitis b and c), cancer or as a side effect of certain medications. the goal of treatment is to reduce symptoms and slow the progression of the disease.  last updated: 9/2/2014

Wikipedia : 71 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Maternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
id Related Disease Score Top Affiliating Genes
1 focal segmental glomerulosclerosis 30.0 CD2AP NPHS1 NPHS2 TRPC6
2 alport syndrome and thin basement membrane nephropathy 12.1
3 anti-basement membrane glomerulonephritis 12.0
4 congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization 11.9
5 hematuria, benign familial 11.2
6 goodpasture syndrome 10.9
7 renal agenesis, unilateral 10.3 CD2AP NPHS2
8 aphthous stomatitis 10.3 ALB NPHS1 NPHS2
9 sick sinus syndrome 3 10.3 CD2AP NPHS1 NPHS2
10 congenital torticollis 10.3 CD2AP NPHS1 NPHS2
11 pauci-immune glomerulonephritis 10.3 NPHS1 NPHS2
12 atopic dermatitis 6 10.3 ALB CD79A
13 frasier syndrome 10.3 CD2AP NPHS1 NPHS2
14 agammaglobulinemia 6 10.3 ACE ALB NPHS1
15 deafness, autosomal recessive 51 10.3 CD2AP NPHS1 NPHS2
16 hypertrichosis of eyelid 10.3 ACE NPHS1 NPHS2
17 schizotypal personality disorder 10.2 ACE ALB TINAG
18 colloid adenoma 10.2 ALB CD79A
19 schneiderian carcinoma 10.2 ALB CD79A
20 spinal cancer 10.2 CD79A MME
21 gilles de la tourette syndrome 10.2 ALB B2M
22 dendritic cell thymoma 10.1 CD79A MME
23 glomerulonephritis 10.1
24 nephrotic syndrome 10.1
25 bronchiolitis 10.1 ALB C3 CD79A PLA2R1
26 plummer's disease 10.1 ALB B2M VTN
27 cerebral cavernous malformations-2 10.1 CD2AP MME NPHS1 NPHS2
28 eye disease 10.1 CD79A MME
29 angiokeratoma 10.1 ALB B2M CD79A
30 venezuelan equine encephalitis 10.1 ALB B2M CD79A
31 henoch-schoenlein purpura 10.1 ALB B2M MME
32 alport syndrome 10.1
33 hemiplegia 10.1 ALB CD2AP CD79A NPHS1 NPHS2
34 early yaws 10.1 ALB B2M CD79A
35 hepatitis 10.1
36 chronic myocardial ischemia 10.1 ACE ALB B2M NPHS2
37 mixed germ cell-sex cord neoplasm 10.1 ACE ALB CD79A NPHS1 NPHS2
38 familial nephrotic syndrome 10.1 ACE ALB CD79A NPHS1 NPHS2
39 acral persistent papular mucinosis 10.0 CD2AP NPHS1 NPHS2 TRPC6
40 anterior foramen magnum meningioma 10.0 ALB B2M CD79A
41 gastric cancer 10.0 CD2AP NPHS1 NPHS2 TRPC6
42 uterine ligament serous adenocarcinoma 10.0 ALB B2M CD79A
43 tall cell variant papillary carcinoma 10.0 B2M CD79A MME
44 46 xy gonadal dysgenesis 10.0 B2M CD79A
45 atrophic vulva 10.0 ALB C3 MPO
46 hepatitis b 10.0
47 transient refractive change 10.0 ACE ALB CD2AP CD79A NPHS1 NPHS2
48 cyclotropia 10.0 C3 CD79A MPO
49 dislocation of ear ossicle 9.9 C3 CD79A MPO
50 immune-complex glomerulonephritis 9.9 C3 CD79A MPO

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM:

614692

MGI Mouse Phenotypes related to Membranous Nephropathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ALB B2M C3 CD2AP CD79A LRP2
2 cardiovascular system MP:0005385 10.02 ACE B2M C3 CD2AP LRP2 MPO
3 hematopoietic system MP:0005397 10.02 ACE B2M C3 CD2AP CD79A HLA-DQA1
4 immune system MP:0005387 9.9 ACE B2M C3 CD2AP CD79A HLA-DQA1
5 liver/biliary system MP:0005370 9.5 MME PECAM1 ACE ALB B2M C3
6 renal/urinary system MP:0005367 9.32 ACE ALB C3 CD2AP CD79A LRP2

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 530)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
2
Cilnidipine Approved Phase 4,Phase 2 132203-70-4 5282138
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Spironolactone Approved Phase 4,Phase 2,Early Phase 1 1952-01-7, 52-01-7 5833
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
Amlodipine Approved Phase 4,Phase 3,Early Phase 1 88150-42-9 2162
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Atenolol Approved Phase 4,Early Phase 1 29122-68-7 2249
9
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 4205-90-7 2803
10
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
11
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-31-9 3440
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
13
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
14
Ramipril Approved Phase 4,Phase 3,Phase 2 87333-19-5 5362129
15
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
16
Bupivacaine Approved, Investigational Phase 4,Phase 2 2180-92-9, 38396-39-3 2474
17
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
18
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
19
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104987-11-3 445643 439492
20
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114798-26-4 3961
21
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
22
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
24
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
25
Amiloride Approved Phase 4,Phase 1,Phase 2 2016-88-8, 2609-46-3 16231
26
Triamterene Approved Phase 4,Phase 3 396-01-0 5546
27
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
28
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
29
Dalteparin Approved Phase 4 9041-08-1
30
Ranolazine Approved, Investigational Phase 4,Phase 1 142387-99-3, 95635-55-5 56959
31
Lisinopril Approved, Investigational Phase 4,Phase 3 83915-83-7 5362119
32
Nisoldipine Approved Phase 4 63675-72-9 4499
33
Benazepril Approved, Investigational Phase 4,Phase 3,Phase 2 86541-75-5 5362124
34
Trandolapril Approved Phase 4 87679-37-6 5484727
35
Verapamil Approved Phase 4 52-53-9 2520
36
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
37
Chlorthalidone Approved Phase 4,Phase 3,Phase 2 77-36-1 2732
38
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
39
Calcium carbonate Approved Phase 4,Phase 2 471-34-1
40
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
41
Felodipine Approved, Investigational Phase 4,Phase 3,Phase 1 72509-76-3 3333
42
Cidofovir Approved Phase 4 113852-37-2 60613
43
Nicardipine Approved Phase 4 55985-32-5 4474
44
Remifentanil Approved Phase 4 132875-61-7 60815
45
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
46
Sertraline Approved Phase 4,Phase 3,Phase 2 79617-96-2 68617
47
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
48
Clotrimazole Approved, Vet_approved Phase 4,Phase 1,Phase 2 23593-75-1 2812
49
Nystatin Approved, Vet_approved Phase 4,Phase 1,Phase 2 1400-61-9 11953884
50
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986

Interventional clinical trials:

(show top 50) (show all 399)
id Name Status NCT ID Phase
1 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4
2 CCB Safety Study in Treatment of Hypertension of ADPKD Unknown status NCT00541853 Phase 4
3 Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients Unknown status NCT01111422 Phase 4
4 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4
5 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
6 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
7 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4
8 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4
9 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4
10 Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4
11 2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula Unknown status NCT00993746 Phase 4
12 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4
13 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4
14 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4
15 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4
16 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4
17 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4
18 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4
19 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4
20 Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4
21 Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children Completed NCT01632046 Phase 4
22 Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in HD Patients(EGESTUDY) Completed NCT00295191 Phase 4
23 Study to Assess Clearances and Bio-compatibility of ELISIO Dialyzer Completed NCT01042327 Phase 4
24 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4
25 The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis Completed NCT01753154 Phase 4
26 Heat Disinfection of HD Water Treatment System in Hemodialysis Patients Completed NCT01138280 Phase 4
27 Loop Diuretics in Chronic Kidney Disease Completed NCT00478543 Phase 4
28 Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) Completed NCT01048879 Phase 4
29 Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis Completed NCT01388270 Phase 4
30 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4
31 The Use of Low Molecular Weight Heparin in Hemodiafiltration Completed NCT00756145 Phase 4
32 Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213) Completed NCT00140985 Phase 4
33 Short Term Effects of FX Dialysers on QOL and Inflammation Completed NCT00291603 Phase 4
34 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4
35 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4
36 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4
37 Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) Completed NCT00234871 Phase 4
38 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4
39 Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD) Completed NCT01380717 Phase 4
40 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4
41 A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) Completed NCT00235014 Phase 4
42 Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose Completed NCT01738945 Phase 4
43 A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD Completed NCT01750294 Phase 4
44 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4
45 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4
46 Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure Completed NCT00124969 Phase 4
47 Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients Completed NCT01265615 Phase 4
48 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4
49 Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus Completed NCT00136773 Phase 4
50 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

id Genetic test Affiliating Genes
1 Membranous Nephropathy 29

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

39
Kidney, Neutrophil, Endothelial, T Cells, Thyroid, Bone, Liver

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 331)
id Title Authors Year
1
Female Patient with Alport Syndrome and Concomitant Membranous Nephropathy: Susceptibility or Association of Two Diseases? ( 28245485 )
2017
2
Membranous nephropathy: integrating basic science into improved clinical management. ( 28065518 )
2017
3
Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. ( 28090051 )
2017
4
Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. ( 28056860 )
2017
5
Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. ( 28084563 )
2017
6
Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy. ( 26809805 )
2016
7
Remarks about the study of an unusual presentation of venous thrombosis in a child with idiopathic membranous nephropathy. ( 27215268 )
2016
8
PLA2R and membranous nephropathy: A 3a88year prospective Australian study. ( 26369693 )
2016
9
A Mechanism for Cancer-Associated Membranous Nephropathy. ( 27192690 )
2016
10
M-type phospholipase A2 receptor (PLA2R) glomerular staining in pediatric idiopathic membranous nephropathy. ( 27921164 )
2016
11
High-density Association Mapping and Interaction Analysis of PLA2R1 and HLA Regions with Idiopathic Membranous Nephropathy in Japanese. ( 27934873 )
2016
12
PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy. ( 27876003 )
2016
13
Serum anti-PLA2R antibodies may be presentA before clinical manifestations of membranous nephropathy. ( 27181779 )
2016
14
The putative role of MALDI-MSI in the study of Membranous Nephropathy. ( 27890680 )
2016
15
A Novel COL4A4 Mutation Identified in a Chinese Family with Thin Basement Membrane Nephropathy. ( 26833262 )
2016
16
Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. ( 27988429 )
2016
17
Donor With Membranous Nephropathy in Preemptive, Living-Related Kidney Transplantation. ( 27546808 )
2016
18
Improvement of idiopathic membranous nephropathy diagnosis with ultrasensitive quantitative detection of anti-phospholipase A2 receptor. ( 27876629 )
2016
19
HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy. ( 27631233 )
2016
20
Erratum to: Phosphotriesterase-related protein sensed albuminuria and conferred renal tubular cell activation in membranous nephropathy. ( 27044255 )
2016
21
Detection and Clinical Significance of Glomerular M-type Phospholipase A2 Receptor in Patients with Idiopathic Membranous Nephropathy. ( 27554390 )
2016
22
Cyclical cyclophosphamide and steroids is effective inA resistant or relapsing nephrotic syndrome due toA M-type phospholipase A2A receptor-related membranous nephropathy after tacrolimus therapy. ( 27181781 )
2016
23
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. ( 27387472 )
2016
24
Membranous nephropathy with crescents associated with levamisole-induced MPO-ANCA vasculitis. ( 27067665 )
2016
25
First report of membranous nephropathy and systemic lupus erythematosus associated with abatacept in rheumatoid arthritis. ( 27462998 )
2016
26
Increased ratio of ICOS(+) /PD-1(+) follicular helper T cells positively correlates with the development of human idiopathic membranous nephropathy. ( 26845249 )
2016
27
Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. ( 27365535 )
2016
28
Effectiveness of sulodexide might be associated with inhibition of complement system in hepatitis B virus-associated membranous nephropathy: An inspiration from a pilot trial. ( 27160380 )
2016
29
Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. ( 27783276 )
2016
30
A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy. ( 27598699 )
2016
31
Treatment with rituximab in idiopathic membranous nephropathy. ( 27994855 )
2016
32
Anti-alpha-enolase antibodies in membranous nephropathy: isotype matters. ( 27026174 )
2016
33
Biomarkers to detect membranous nephropathy in Chinese patients. ( 27634909 )
2016
34
Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy? ( 27493452 )
2016
35
IFI27 Is a Useful Genetic Marker for Diagnosis of Immunoglobulin A Nephropathy and Membranous Nephropathy Using Peripheral Blood. ( 27100186 )
2016
36
Membranous Nephropathy with an Enhanced Granular Expression of Thrombospondin Type-1 Domain-containing 7A in a Pregnant Woman. ( 27629964 )
2016
37
Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases. ( 27624606 )
2016
38
Necrotizing and crescentic glomerulonephritis with membranous nephropathy in a patient exposed to levamisole-adulterated cocaine. ( 26985374 )
2016
39
Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy. ( 27199983 )
2016
40
Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. ( 27942609 )
2016
41
Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. ( 27214550 )
2016
42
Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. ( 27153925 )
2016
43
Alteration of histone H3K4 methylation in glomerular podocytes associated with proteinuria in patients with membranous nephropathy. ( 27855638 )
2016
44
How many podocyte autophagosomes are there in immunoglobulin A nephropathy and idiopathic membranous nephropathy? ( 27580730 )
2016
45
Membranous Nephropathy in the Kidney Allograft. ( 27646575 )
2016
46
An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. ( 27436855 )
2016
47
Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy. ( 27058841 )
2016
48
Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy. ( 27179439 )
2016
49
Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy. ( 27974710 )
2016
50
Immunosuppression in idiopathic membranous nephropathy: A double-edge sword. ( 27382985 )
2016

Variations for Membranous Nephropathy

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

Pathways related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.05 B2M CD2AP CD79A MPO PECAM1
2 11.74 C3 HLA-DQA1 MPO PLA2R1
3 10.97 CD2AP MME NPHS1 NPHS2 TRPC6 VTN
4 10.67 CD2AP NPHS1 NPHS2 TRPC6

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.73 ACE B2M CD79A PECAM1
2 lysosome GO:0005764 9.72 ACE HLA-DQA1 LRP2 MPO TINAG
3 extracellular exosome GO:0070062 9.47 ACE ALB B2M C3 CD2AP LRP2
4 rough endoplasmic reticulum lumen GO:0048237 9.26 LRPAP1 VTN
5 slit diaphragm GO:0036057 9.13 NPHS1 NPHS2 TRPC6
6 extracellular region GO:0005576 10.07 ACE ALB B2M C3 LRPAP1 MPO
7 plasma membrane GO:0005886 10.03 ACE B2M C3 CD2AP CD79A HLA-DQA1
8 extracellular space GO:0005615 10.01 ACE ALB B2M C3 MPO PECAM1
9 integral component of plasma membrane GO:0005887 10 CD79A HLA-DQA1 MME NPHS1 NPHS2 PLA2R1

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.77 B2M C3 HLA-DQA1 TINAG VTN
2 neutrophil degranulation GO:0043312 9.55 B2M C3 MME MPO PECAM1
3 beta-amyloid metabolic process GO:0050435 9.4 ACE MME
4 angiotensin maturation GO:0002003 9.32 ACE MME
5 replicative senescence GO:0090399 9.26 MME PLA2R1
6 receptor-mediated endocytosis GO:0006898 9.02 ALB LRP2 PLA2R1 TINAG VTN
7 regulation of receptor-mediated endocytosis GO:0048259 8.96 CD2AP LRPAP1

Molecular functions related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 8.96 TINAG VTN
2 exopeptidase activity GO:0008238 8.62 ACE MME

Sources for Membranous Nephropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....